Girentuximab Completed Phase 1 Trials for Renal Cancer / Renal Neoplasms / Renal Cell Carcinoma (RCC) Treatment

Indications	Status	Purpose	Phase
DBCOND0032584 (Renal Cancer) DBCOND0030039 (Renal Neoplasms) DBCOND0038284 (Renal Cell Carcinoma (RCC))	Completed	Treatment	1

clinicaltrials.gov Identifier	Title	Drugs
NCT00199875	Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250	Girentuximab (DB05304) Yttrium Y-90 (DB13076)